Peptide Receptor Types: GPCRs, Melanocortin, and GH Secretagogue Receptors

The biological effects of any peptide are determined primarily by which receptors it binds and where in the body those receptors are expressed. Two peptides with entirely different amino acid sequences may produce similar physiological effects if they activate the same receptor; conversely, a single peptide may have diverse effects throughout the body if its receptor is expressed in multiple tissues. Understanding peptide receptor types — their molecular structure, signaling mechanisms, and tissue distribution — is foundational to understanding why research peptides do what they do.

The Receptor Landscape: A Structural Overview

Cellular receptors are proteins embedded in cell membranes (or located intracellularly) that recognize specific molecular signals and transduce them into cellular responses. Peptides interact with several major receptor classes:

• G protein-coupled receptors (GPCRs): The largest superfamily, mediating most endocrine and neuropeptide signaling
• Receptor tyrosine kinases (RTKs): Insulin, IGF-1, and EGF receptors belong here
• Cytokine receptors / JAK-STAT pathway receptors: Growth hormone, leptin, and many interleukins signal through this class
• Ion channel-coupled receptors: Some neuropeptides modulate ligand-gated ion channels
• Nuclear receptors: Not relevant for peptides, which cannot cross cell membranes to reach nuclear receptors

The vast majority of therapeutically relevant peptides act through GPCRs, so this class deserves detailed attention.

G Protein-Coupled Receptors: The Master Class

GPCRs are the largest family of membrane receptors in the human genome — over 800 genes encode GPCRs, of which roughly 400 respond to endogenous ligands including peptides, hormones, and neurotransmitters. All GPCRs share a characteristic seven-transmembrane (7-TM) topology: a single polypeptide chain that loops back and forth through the cell membrane seven times, creating an extracellular ligand-binding domain and an intracellular domain that couples to G proteins.

The G protein mechanism:

1. Peptide binds to the extracellular or transmembrane binding pocket
2. Receptor undergoes conformational change
3. Intracellular G protein (heterotrimer of Gα, Gβ, Gγ) is activated — GDP on Gα is exchanged for GTP
4. Gα dissociates and activates downstream effectors:
   • Gαs: Activates adenylyl cyclase → increased cAMP → PKA activation
   • Gαi: Inhibits adenylyl cyclase → decreased cAMP
   • Gαq: Activates phospholipase C → IP3 + DAG → calcium release + PKC activation
   • Gα12/13: Activates Rho GTPases → cytoskeletal changes

The specific G protein subtype that a receptor couples to determines the downstream signaling character. Many peptide receptors can couple to multiple G protein types depending on ligand, cell type, and context — a phenomenon called biased agonism that is increasingly exploited in drug design.

Beta-arrestin signaling: In addition to G protein pathways, GPCRs can signal through beta-arrestin after receptor phosphorylation. Beta-arrestin-mediated signaling is responsible for receptor desensitization (internalization) and activates MAPK/ERK pathways independently of G proteins. Some next-generation peptide analogs are designed as "biased agonists" that preferentially activate G protein signaling while minimizing beta-arrestin recruitment, reducing desensitization.

Melanocortin Receptors (MC1R–MC5R)

The melanocortin receptor family consists of five subtypes (MC1R through MC5R), all of which are GPCRs coupling to Gαs (cAMP pathway). They are activated by melanocortin peptides derived from pro-opiomelanocortin (POMC): alpha-MSH, beta-MSH, gamma-MSH, and ACTH.

MC1R: Expressed primarily in melanocytes. Activation by alpha-MSH stimulates melanin production (skin darkening). Melanotan I and Melanotan II both activate MC1R, producing tanning. MC1R variants are associated with red hair and fair skin phenotypes.

MC2R: The ACTH receptor, expressed exclusively in the adrenal cortex. Activation stimulates cortisol and aldosterone synthesis. This extreme receptor selectivity is why ACTH injections cause adrenal effects but not tanning — despite being a melanocortin peptide.

MC3R: Expressed in the brain (hypothalamus) and gut. Involved in energy homeostasis and modulation of inflammatory responses. Less studied than MC4R but gaining research attention.

MC4R: The most pharmacologically significant melanocortin receptor for body composition. Expressed in the hypothalamus, MC4R is a major regulator of appetite, energy expenditure, and sexual function. Activating MC4R suppresses appetite and increases basal metabolic rate. Loss-of-function MC4R mutations are the most common genetic cause of early-onset obesity in humans. PT-141 (bremelanotide) activates MC4R in the CNS to produce pro-erectile and pro-sexual arousal effects.

MC5R: Expressed in exocrine glands, immune cells, and skeletal muscle. MC5R regulates sebaceous gland secretions and may play roles in immune modulation.

Endogenous antagonists: The melanocortin system also has endogenous inhibitors. Agouti signaling protein (ASIP) is an MC1R and MC4R antagonist expressed in hair follicles; agouti-related protein (AgRP) is a hypothalamic MC3R and MC4R inverse agonist that promotes feeding behavior. This push-pull between melanocortin agonists and AgRP/ASIP is a central regulatory axis in energy homeostasis.

Research peptides at melanocortin receptors: Melanotan II is a non-selective melanocortin agonist activating MC1R, MC3R, MC4R, and MC5R. This broad activity explains its multiple effects: tanning (MC1R), appetite suppression (MC3R/MC4R), sexual arousal (MC4R), and potential immune effects (MC5R). PT-141 (bremelanotide) is a more selective analog with enhanced MC4R activity, used clinically for hypoactive sexual desire disorder.

Growth Hormone Secretagogue Receptor (GHSR-1a)

GHSR-1a is the ghrelin receptor, a GPCR that couples to Gαq and Gαi in different tissues. It is the receptor for all GHRP-class peptides (ipamorelin, GHRP-2, GHRP-6, hexarelin) and for the non-peptide secretagogue MK-677.

Distribution: GHSR-1a is expressed in:

• Anterior pituitary somatotrophs: direct GH release
• Hypothalamus: somatostatin suppression, appetite regulation via AgRP/NPY neurons
• Hippocampus and cortex: memory, neuroprotection, anxiolytic effects
• Gastrointestinal tract: appetite stimulation, gastric motility
• Cardiac muscle: cardioprotective effects (independent of GH)
• Adipose tissue, pancreas, adrenal gland: metabolic effects

Constitutive activity: GHSR-1a is unusual among GPCRs in having high constitutive activity — it signals significantly even in the absence of ghrelin. This basal signaling contributes to tonic appetite stimulation and explains why inverse agonists (not just antagonists) are needed to fully suppress ghrelin signaling.

Functional selectivity: Ipamorelin's superior selectivity profile relative to GHRP-6 or hexarelin arises from its specific binding mode at GHSR-1a. While all GHRPs activate the GH-releasing pathway, ipamorelin's interaction geometry minimizes activation of the cortisol/ACTH and prolactin pathways — making it more suitable for long-term use. This is receptor-level functional selectivity (biased agonism).

For a detailed examination of GHSR-1a pharmacology in the context of GHRH/GHRP combinations, see our GHRH vs GHRP peptides guide.

GHRH Receptor (GHRHR)

The growth hormone-releasing hormone receptor is a class B GPCR that couples to Gαs. It is expressed primarily in anterior pituitary somatotrophs, with lower expression in the brain, lung, and other tissues. GHRHR activation increases cAMP, PKA activity, and ultimately triggers calcium-dependent GH granule exocytosis, as well as GH gene transcription.

Class B GPCRs (also called secretin receptors) are structurally distinct from class A GPCRs. They have a large extracellular N-terminal domain that is crucial for ligand binding — the peptide hormone makes initial contact with this N-terminal domain, then the C-terminal portion of the peptide engages the transmembrane binding pocket. This two-step mechanism is called the "two-domain" binding model.

Insulin and IGF-1 Receptors (Receptor Tyrosine Kinases)

The insulin receptor (IR) and IGF-1 receptor (IGF-1R) are receptor tyrosine kinases (RTKs) — not GPCRs. They exist as disulfide-linked tetrameric complexes that span the membrane. Ligand binding causes conformational changes that activate the intrinsic tyrosine kinase domain on the intracellular beta subunits, leading to autophosphorylation and recruitment of signaling scaffolds (IRS-1/2, Shc).

The two major downstream pathways are:

• PI3K/Akt: Regulates glucose uptake, protein synthesis, and cell survival
• MAPK/ERK: Regulates cell growth, differentiation, and proliferation

The insulin and IGF-1 receptors can form hybrid receptors (IR/IGF-1R heterotetramers) with intermediate ligand binding properties. This is why high-dose insulin has some IGF-1-like anabolic effects and vice versa — the receptors are structurally and pharmacologically related.

Receptor Expression and Tissue Selectivity

The same peptide can produce different effects in different tissues simply because receptor subtype expression patterns vary:

• A melanocortin peptide that activates MC1R in skin causes tanning
• The same peptide activating MC4R in the hypothalamus suppresses appetite
• Activating MC2R in the adrenal gland (only for ACTH, not MSH) stimulates cortisol

This tissue-level selectivity is why receptor subtype mapping is so important in drug development. Ideal peptide drugs activate only the desired receptor subtype(s) in the desired tissue(s). This explains the pharmaceutical effort to develop MC4R-selective agonists for obesity that avoid MC1R activation (and associated pigmentation changes) or MC5R activation (and potential immune effects).

Receptor Desensitization and Downregulation

Sustained peptide receptor activation leads to two adaptive responses:

Desensitization (short-term): GPCR kinases (GRKs) phosphorylate the activated receptor. Beta-arrestin is recruited, physically uncoupling the receptor from G proteins and preventing further signaling. This process begins within seconds to minutes of receptor activation.

Internalization/downregulation (longer-term): Beta-arrestin recruits the receptor to clathrin-coated pits for endocytosis. Internalized receptors may be recycled back to the cell surface (resensitization) or degraded in lysosomes (downregulation). Sustained over-stimulation leads to net receptor downregulation — reduced total receptor number — which decreases the tissue's responsiveness to the peptide.

These mechanisms are why pulsatile dosing protocols are physiologically superior to continuous delivery for most peptide hormones, and why cycling peptide research protocols is generally recommended.

Frequently Asked Questions

Q: How do researchers determine which receptor a peptide binds? Binding assays using radiolabeled or fluorescently labeled peptides against panels of expressed receptors identify binding affinity (Ki values). Functional assays (measuring cAMP, IP3, or receptor phosphorylation) confirm signaling activity. Genetic knockout studies (cells or animals lacking specific receptors) confirm which receptor mediates observed effects.

Q: What does "selective" mean for a peptide receptor? Selectivity describes a peptide's preference for one receptor subtype over others in the same family. Ipamorelin is considered selective for GHSR-1a's GH-releasing signaling pathway while producing minimal activity at pathways mediating cortisol and prolactin release. Selectivity is relative, not absolute — it depends on dose.

Q: Can the same peptide act as an agonist at one receptor and an antagonist at another? Yes. A peptide may activate one receptor subtype (agonist, eliciting a downstream response) while blocking another subtype (antagonist, occupying the receptor without activating it). This is relevant when a peptide has structural similarities to multiple endogenous ligands.

Q: Why do some peptides cause receptor downregulation faster than others? This depends on how strongly the peptide promotes beta-arrestin recruitment and receptor internalization. Peptides that act as biased agonists favoring G protein signaling over beta-arrestin recruitment cause slower desensitization. The potency and duration of receptor occupancy also matter — brief, intense activation (pulses) typically causes less downregulation than sustained activation.

Q: What is an allosteric modulator and how is it relevant to peptides? An allosteric modulator binds a receptor at a site other than the primary binding site (the orthosteric site), changing the receptor's responsiveness to its natural ligand without replacing it. Positive allosteric modulators (PAMs) enhance the effect of the natural ligand; negative allosteric modulators (NAMs) reduce it. Some drug candidates modulate GHS receptors or melanocortin receptors allosterically to achieve more nuanced control of signaling.